Write in a clean editor, then format for The Botulinum J in one click — DocuGuru applies the official Inderscience template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
The Botulinum J is a peer-reviewed journal published by Inderscience, covering Botulinum Toxin and Related Neurological Disorders, Neurological disorders and treatments, Hereditary Neurological Disorders.
| Publisher | Inderscience |
|---|---|
| Reference style | Author–year (Harvard/AGSM) Author–year — (Smith, 2023) in the text Smith, A., Jones, B. and Lee, C. (2023) 'A representative article title', The Botulinum J, 12(3), pp. 45–58.
Formats any DOI in The Botulinum J style. No sign-up. |
| Publishes research in | Botulinum Toxin and Related Neurological Disorders Neurological disorders and treatments Hereditary Neurological Disorders Parkinson's Disease Mechanisms and Treatments Genetic Neurodegenerative Diseases |
| ISSN | 1754-7318 |
| h-index | 9 |
| i10-index | 9 |
| Total citations | 424 |
| Top institutions publishing here | University of Massachusetts Dartmouth |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
An overall picture of the botulinum toxins is provided, linking the recent developments in their molecular and cellular aspects to the physiological actions. The pathophysiological aspects of botulinum poisoning (clinical symptoms and physical findings, synaptic effects at the motor and non-motor nerve terminals) and indirect consequences (muscle atrophy, transient formation of new end-plates) are described.…
Dysport? (botulinum type A toxin; BoNT-A) 500 LD50 unit vial was first licensed for clinical use in 1990. Inter-batch reproducibility and comparability of the Dysport toxin?haemagglutinin complex must ensure the consistency of clinical material. The specific potency (potency per unit weight of toxin protein) provides the level of protein administered per injection. We report a…
Botulism had mortality rates >60% before the 1950s. We reviewed confirmed botulism cases in the USA during 1975-2009 including infant, foodborne, wound, and other/unknown acquisition categories, and calculated mortality ratios. We created a multivariate logistic regression model for non-infant cases (foodborne, wound, and other/unknown). Overall mortality was 3.0% with 109 botulism-related deaths among 3,618 botulism…
The Botulinum Toxin ELISA effectively provided presumptive identification of toxin in 1381 investigation samples including clinical specimens, suspect foods, and cultures. Additionally, the ELISA detected all toxins produced by a panel of stock strains representing known subtypes and was negative for non-botulinum toxin producing Clostridium and enteric pathogens. ELISA results were reproducible both within the…
Botulinum toxin type A is a complex composed of the biologically active neurotoxin, several hemagglutinins and other nontoxic proteins. After intramuscular injection these complexing proteins do not have any therapeutic effect. However, they protect the neurotoxin from harsh environmental conditions, e.g., low intragastral pH after oral ingestion. NT201, a BoNT/A drug product devoid of complexing…
